The 23 most recent market catalysts affecting $CYTK, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 65
Cytokinetics Seeks FDA Label Update for Myqorzo
Cytokinetics is pursuing an FDA label update for Myqorzo, an approved hypertrophic cardiomyopathy treatment, to incorporate favorable Phase 3 Maple-HCM trial results. The trial dem…
Nov 9, 2026
Corporate Catalyst
Neutral
Impact 75
Cytokinetics Presents New Aficamten Data at HCMS Scientific Sessions
Cytokinetics presented new data for its drug candidate aficamten at the HCMS Scientific Sessions, including late-breaking Phase 3 results from the ACACIA-HCM trial and new data fro…
Nov 5, 2026
Corporate Catalyst
Bullish
Impact 65
RBC Capital Markets Comments on Cytokinetics' Myqorzo Revenue Potential
RBC Capital Markets published a report on November 5, 2026, indicating that Cytokinetics' product, Myqorzo, is expected to start contributing to revenue growth in 2027. This is sig…
Nov 5, 2026
Corporate Catalyst
Bearish
Impact 55
Leerink Partners Maintains Cytokinetics at Outperform, Lowers Price Target
Leerink Partners reaffirmed its 'Outperform' rating for Cytokinetics, indicating continued confidence in the company's prospects. However, the firm simultaneously lowered its price…
Nov 4, 2026
Corporate Catalyst
Bullish
Impact 85
Cytokinetics Reports Third Quarter 2026 Financial Results
Cytokinetics announced third-quarter 2026 financial results that surpassed analyst expectations for both revenue and loss per share, indicating better operational performance than …
Nov 2, 2026
Corporate Catalyst
Neutral
Impact 65
Cytokinetics Announces Upcoming Presentations at the Hypertrophic Cardiomyopathy Medical Society Scientific Sessions
Cytokinetics announced it will present new data from its ACACIA study on aficamten's effect on cardiac structure and function in nonobstructive hypertrophic cardiomyopathy at the H…
Oct 19, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Joseph Pantginis has reiterated a 'Buy' rating for Cytokinetics (CYTK) and maintained a $140 price target. This is a rout…
Oct 19, 2026
Corporate Catalyst
Bullish
Impact 75
Cytokinetics Receives Notice Of Compliance From Health Canada Authorizing Treatment Use Of MYQORZO For Symptomatic Obstructive Hypertrophic Cardiomyopathy
Cytokinetics has received a Notice of Compliance from Health Canada, authorizing MYQORZO for the treatment of symptomatic obstructive hypertrophic cardiomyopathy (oHCM) in adult pa…
Oct 16, 2026
Corporate Catalyst
Neutral
Impact 55
William Blair Initiates Coverage On Cytokinetics with Outperform Rating
William Blair analyst Alethia Young has initiated coverage on Cytokinetics (CYTK) with an Outperform rating. This event is significant because analyst initiations, especially with …
Oct 12, 2026
Corporate Catalyst
Neutral
Impact 55
Cytokinetics Presents Additional Data From Assessment Comparing Aficamten To Placebo On Cardiac Endpoints In Adults With Non-Obstructive HCM At HFSA Annual Scientific Meeting 2026
Cytokinetics announced the presentation of additional data from its ACACIA-HCM study for Aficamten at the Heart Failure Society of America Annual Scientific Meeting 2026. This even…
Oct 8, 2026
Corporate Catalyst
Bullish
Impact 55
RBC Capital Maintains Outperform on Cytokinetics, Raises Price Target to $113
RBC Capital analyst Leonid Timashev has maintained an 'Outperform' rating on Cytokinetics (CYTK) and raised the price target from $112 to $113. This action signals continued bullis…
Aug 31, 2026
Corporate Catalyst
Neutral
Impact 55
HC Wainwright & Co. Reiterates Buy on Cytokinetics, Maintains $140 Price Target
This 8-K filing discloses that HC Wainwright & Co. analyst Joseph Pantginis has reaffirmed a 'Buy' rating and a $140 price target for Cytokinetics (CYTK). This is a routine analyst…
Aug 31, 2026
Corporate Catalyst
Bullish
Impact 75
Reported Earlier, Cytokinetics Says New Trial Data Strengthens Case For Aficamten Across Heart Condition Types
Cytokinetics released additional positive data from its ACACIA-HCM and MAPLE-HCM trials for aficamten, presented at the ESC Congress 2026 and published in leading medical journals.…
Aug 28, 2026
Corporate Catalyst
Bullish
Impact 85
Cytokinetics shares are trading lower. The company reported pivotal Phase 3 ACACIA‑HCM results showing aficamten met both dual primary endpoints, with significant improvements in patient quality‑of‑life scores and exercise capacity versus placebo.
The headline presents a classic 'sell the news' scenario where a company's stock declines despite positive clinical trial results. This often occurs when the market has already lar…
Aug 20, 2026
Corporate Catalyst
Neutral
Impact 85
Cytokinetics Announces Primary Results From Phase 3 Trial Of Aficamten In Non-Obstructive Hypertrophic Cardiomyopathy To Be Presented August 28 At ESC Congress
The upcoming presentation of Phase 3 trial results for Aficamten is a critical binary event for Cytokinetics. Positive data could unlock significant value, leading to potential FDA…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
Barclays Maintains Overweight on Cytokinetics, Raises Price Target to $110
Barclays analyst Emily Field has maintained an 'Overweight' rating on Cytokinetics and raised the price target from $95 to $110. This action signals a strengthened positive outlook…
Aug 13, 2026
Corporate Catalyst
Bullish
Impact 65
JP Morgan Maintains Overweight on Cytokinetics, Raises Price Target to $103
JP Morgan analyst Tessa Romero has maintained an 'Overweight' rating on Cytokinetics (CYTK) and raised the price target from $97 to $103. This move indicates a strengthened positiv…
Aug 10, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Buy on Cytokinetics, Raises Price Target to $112
Truist Securities analyst Srikripa Devarakonda maintained a 'Buy' rating on Cytokinetics and raised the price target from $106 to $112. This action signals increased confidence fro…
Aug 7, 2026
Corporate Catalyst
Bearish
Impact 55
RBC Capital Maintains Outperform on Cytokinetics, Lowers Price Target to $112
RBC Capital analyst Leonid Timashev maintained an 'Outperform' rating for Cytokinetics (CYTK) but adjusted the price target downwards from $117 to $112. This action signals that wh…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Citizens Maintains Market Outperform on Cytokinetics, Raises Price Target to $110
Citizens analyst Jason N. Butler has reiterated a 'Market Outperform' rating for Cytokinetics and raised the price target from $105 to $110. This action signals continued bullish s…
Aug 7, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Cytokinetics, Raises Price Target to $112
Needham analyst Serge Belanger maintained a 'Buy' rating on Cytokinetics (CYTK) and raised the price target from $102 to $112. This action signals an analyst's increased conviction…
Aug 6, 2026
Corporate Catalyst
Bearish
Impact 85
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate
Cytokinetics (CYTK) reported Q2 earnings with a loss of $(1.50) per share, beating the analyst consensus of $(1.63). This 7.98% beat on EPS, coupled with sales of $28.624 million w…
Jul 30, 2026
Corporate Catalyst
Bullish
Impact 75
Cytokinetics Receives UK Marketing Authorization For MYQORZO For Treatment Of Symptomatic Obstructive Hypertrophic Cardiomyopathy In Adult Patients
Cytokinetics announced that its drug, MYQORZO (aficamten), has received marketing authorization in the UK and positive guidance from NICE for treating symptomatic oHCM. This is a s…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.